DiscoverLung Cancer ConsideredFDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC
FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

Update: 2024-04-02
Share

Description

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marcelo Corassa. FLAURA2 was first presented at the 2023 WCLC in Singapore by Dr. Jänne.
Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

IASLC